Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04661072

Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care

The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.

Recruiting

Interested in participating?

Request Info

Key information

Age range

13 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Yale University

New Haven, Connecticut, 06511, United States

Location status: Recruiting

Location contact

Alla Vash-Margita, MD, FACOG

PRINCIPAL_INVESTIGATOR

Monica G Konstantino, RN

CONTACT

[email protected]

203-785-5816

About this study

Aim 1: To identify female subjects diagnosed with a Congenital Uterine Anomaly (CUA) receiving care at Yale New Haven Health.

Aim 2: Identify (i) the prevalence of renal, breast, ovarian, uterine and vaginal cancers associated with CUAs, and (ii) the association of environmental factors, via a survey obtained by phone, email or interview.

Aim 3: Conduct genetic evaluation of the index subjects, parents, sister(s) (as feasible), and female offspring to identify potential causes and patterns of inheritance using whole exome sequencing (WES) and microarray.

Following informed consent, blood will be collected for genetic evaluation. DNA will be extracted from EDTA-blood and analyzed using an integrated approach of microarray for copy number variations (CNV), and Whole Exome Sequencing (WES) for Single Nucleotide Variation (SNV).

Undertaking review of the medical records will identify the cohort of patients we wish to survey to then ascertain further information regarding their CUA diagnosis and other related details. The information to be elicited from the survey are outlined in the attached survey questions. Key associations we seek to investigate include (1) the type and prevalence of renal, breast, ovarian, uterine and vaginal cancers among patients with Mullerian Anomaly, and (2) identifying potential in-utero exposure to particular environmental agents in patients with CUAs.

Review of the medical records will enable us to undertake this first key step of establishing a cohort of subjects with MA and an initial data set related to their specific health information. We anticipate further investigations may build upon this initial data set, both with the cohort established, and more broadly with collaborators and additional national and international cohorts of patients with MA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • females
  • age: 13 or older
  • encounters limited to: Yale New Haven Hospital, Bridgeport Hospital, Greenwich Hospital and Lawrence+ Memorial Hospital.
  • diagnosis of any variation of CUA

Exclusion criteria

  • who will decline to participate in a study upon contact
  • non-English speaking except Spanish speaking
  • unable to participate in consent or assent process due to mental disability

Treatment and study plan

Primary outcomes

  1. Prevalence of breast cancer in women with CUA's compared to women without CUA's

    Time frame: 6-months

    Prevalence of breast cancer in women with CUA's compared to women without CUA's will be measured

  2. Prevalence of ovarian cancer in women with CUA's compared to women without CUA's

    Time frame: 6-months

    Prevalence of ovarian cancer in women with CUA's compared to women without CUA's will be measured

  3. Prevalence of uterine cancer in women with CUA's compared to women without CUA's

    Time frame: 6-months

    Prevalence of uterine cancer in women with CUA's compared to women without CUA's will be measured

  4. Prevalence of cervical cancer in women with CUA's compared to women without CUA's

    Time frame: 6 month

    Prevalence of cervical cancer in women with CUA's compared to women without CUA's will be measured

  5. Prevalence of vaginal cancer in women with CUA's compared to women without CUA's

    Time frame: 6 month

    Prevalence of vaginal cancer in women with CUA's compared to women without CUA's will be measured

  6. Prevalence of renal cancer in women with CUA's compared to women without CUA's

    Time frame: 6 month

    Prevalence of renal cancer in women with CUA's compared to women without CUA's will be measured

Secondary outcomes

  1. Whole exome sequencing (WES) and microarray

    Time frame: 24 months

    WES and microarray will be conducted in subjects with CUAs. The discovery of possible causative genes would be measured using yes/no outcome variable.

Study contacts

Contact information is provided by the study sponsor or research team.

Alla Vash-Margita, MD

CONTACT

[email protected]

203-785-4010

Miranda Margetts, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Dec 9, 2020
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.